Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Han, Rui Xian ^a,b   Liu, Xu ^a   Pan, Pan ^a,b   Jia, Ying Jie ^a   Yu, Jian Chun ^a  

^a FIRST TEACHING HOSPITAL OF TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CARCINOMA, NON-SMALL-CELL LUNG; COCULTURE; CYTOKINE INDUCED KILLER CELL; CYTOLOGY; DENDRITIC CELL; DISEASE FREE SURVIVAL; FACTUAL DATABASE; HUMAN; IMMUNOTHERAPY; LUNG NEOPLASMS; META ANALYSIS; MORTALITY; REMISSION; SURVIVAL RATE; TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COCULTURE TECHNIQUES; CYTOKINE-INDUCED KILLER CELLS; DATABASES, FACTUAL; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84907523487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108958     Document Type: Review

References (34)

1. Jemal A, Bray F, Center M, Ferlay J, Ward E, et al. (2011) Global cancer statistics. Ca Cancer J Clin 61: 69-90.
2. Zheng Y, Li R, Zhang X, Ren X (2013) Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest 31: 197-205.
3. Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf IGH (2011) Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one? Leukemia Research 35: 1136-1142.
4. DeVita V, Rosenberg S (2012) Two hundred years of cancer research. N Engl J Med 366: 2207-2013.
5. Kelly RJ, Gulley JL, Giaccone G (2010) Immunotherapy for non-small cell lung cancer. Clin Lung Cancer 11: 228-237.
6. Kakimi K, Nakajima J, Wada H (2009) Active specific immunotherapy and celltransfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 65: 1-8.
7. Jäkel CE, Schmidt-Wolf IG (2014) An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther: Epub ahead of print.
8. Olioso P, Giancola R, Riti MD, Contento A, Accorsi P, et al. (2009) Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 27: 130-139.
9. Ma Y, Zhang Z, Tang L, Xu Y, Xie Z, et al. (2012) Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 14: 483-493.
10. Tao L, Huang G, Shi S, Chen L (2014) Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol 31: 777(771-778).
11. Wongkajornsilp A, Wamanuttajinda V, Kasetsinsombat K, Duangsa-ard S, Sangiamsuntorn K, et al. (2013) Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3+CD56+ subset through the co-culturing dendritic cells. PloS One 8: epub ahead of printing.
12. Wang X, Yu W, Li H, Yu J, Zhang X, et al. (2014) Can the dual-functional capability of CIK cells be used to improve antitumor effects? Cell Immunol 287: 18-22.
13. Wang QJ, Wang H, Pan K, Li YQ, Huang LX, et al. (2010) Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer 29: 641-648.
14. Zhong R, Han B, Zhong H (2014) A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 35: 987-994.
15. Holt GE, Podack ER, Raez LE (2011) Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy 8: 43-54.
16. Huang X, Chen Y, Song H, Huang G, Chen L (2011) Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol 17: 3002-3011.
17. Rao B, Han M, Wang L, Gao X, Huang J, et al. (2011) Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J Transl Med 9: 17-27.
18. Liu L, Zhang W, Qi X, Li H, Yu J, et al. (2012) Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 18: 1751-1759.
19. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
20. Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Available: http://www.cochrane-handbook.org/. Accessed: 2012 Nov 13.
21. Chrischilles E, Pendergast J, Kahn K, Wallace R, Moga D, et al. (2010) Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 28: 620-627.
22. Wu S, Keresztes RS (2011) Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Invest 29: 460-471.
23. Kautio AL, Haanpaa M, Kautiainen H, Leminen A, Kalso E, et al. (2011) Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res 31: 3493-3496.
24. Jackson D, White I, Riley R (2012) Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 31: 3805-3820.
25. Wu C, Jiang J, Shi L, Xu N (2008) Prospective study of chemotherapy in combination with CIK cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28: 3997-4002.
26. Zhao G, Huang Y, Ye L, Duan L, Zhou Y, et al. (2009) Therapeutic efficacy of traditional vein chemotherapy and bronchial arterial infusion combining with CIKs on III stage non-small cell lung cancer. Chin J Lung Cancer 12: 1000-1004.
27. Zhong R, Teng J, Han B, Zhong H (2011) Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 60: 1497-1502.
28. Shi S, Ma T, Li C, Tang X (2012) Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 98: 314-319.
29. Yang L, Ren B, Li H, Yu J, Cao S, et al. (2013) Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62: 65-73.
30. Li H, Wang CL, Yu JP, Cao S, Wei F, et al. (2009) Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 11: 1076-1083.
31. Tucker ZCG, Laguna BA, Moon E, Singhal S (2012) Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat Rev 38: 650-661.
32. Aerts J, Hegmans J (2013) Tumor-specific cytotoxic T cells arecrucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 73: 2381-2388.
33. Hiret S, Senellart H, Bennouna J (2010) Molecular biology of lung cancer series. Rev Mal Respir 27: 954-958.
34. Wang J, Zou Z, Xia H, He J, Zhong N, et al. (2012) Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PLoS One 7: 1-12.